Our initial investment in the personalized diagnostics space, CardioDx developed and is now marketing Corus® CAD, a gene expression algorithm-based blood test for the detection of significant atherosclerotic coronary artery disease (CAD). The test was developed in collaboration with leading academic groups, including Duke University. The test is regulated under CLIA guidelines and performed at an onsite laboratory in Palo Alto.
Strategically focused on coronary artery disease, cardiac arrhythmia, and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies.
Palo Alto, CA
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.